Guidance on the use of gemcitabine for the treatment of pancreatic cancer

National Institute for Clinical Excellence
Record ID 32002000343
English
Authors' objectives:

To provide guidance on the use of gemcitabine for the treatment of pancreatic cancer.

Authors' recomendations: Guidance 1.1 Gemcitabine may be considered as a treatment option for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky performance score of 50 or more, where first line chemotherapy is to be used. 1.2 Gemcitabine is not recommended for patients who are suitable for potentially curative surgery, or patients with a Karnofsky score of less than 50. 1.3 There is insufficient evidence to support the use of gemcitabine as a second line treatment in patients with pancreatic adenocarcinoma.
Authors' methods: Systematic review
Details
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Pancreatic Neoplasms
Contact
Organisation Name: National Institute for Clinical Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.